Company Monitoring Page for Acceleron

latest headlines for company on cafepharma

FDA threatens drugmaker with fines for failing to report trial results
RAPS.org
Wed, 04/28/21 - 09:58 pm
Tags:
Acceleron, FDA, clinical trials
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Wed, 04/8/20 - 10:37 am
Tags:
Acceleron, PAH, FDA, breakthrough therapy, sotatercept
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Mon, 04/6/20 - 10:30 am
Tags:
Bristol-Myers Squibb, Acceleron, FDA, Reblozyl, MDS
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
Tags:
FDA, regulatory, Bristol-Myers Squibb, ozanimod, Esteve, E-58425, Fabre-Kramer, AstraZeneca, Imfinzi, Astellas, Vesicare, AbbVie, Neurocrine, Orlissa, Sanofi, MenQuadfi, opicapone, Acceleron, Reblozyl
Acceleron ditches midstage drug after flop
Fierce Biotech
Tue, 03/10/20 - 10:38 am
Tags:
Acceleron, Charcot-Marie-Tooth, clinical trials, ACE-083
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
Sun, 02/23/20 - 06:17 pm
Tags:
beta thalassemia, rare disease, drug development, Acceleron, Bristol-Myers Squibb, Bluebird Bio, Sangamo Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Syros Pharmaceuticals
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Tue, 01/28/20 - 11:09 am
Tags:
Acceleron, sotatercept, PAH, JNJ, Bellerophon Therapeutics, United Therapeutics, Vivus, Arena, Novartis
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Mon, 01/27/20 - 10:47 pm
Tags:
Acceleron, PAH, clinical trials, sotatercept
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Pharmaceutical Business Review
Wed, 01/1/20 - 06:51 pm
Tags:
Acceleron, Fulcrum Therapeutics, R&D, small molecule drugs, pulmonary
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Wed, 12/4/19 - 10:34 am
Tags:
Bristol-Myers Squibb, Acceleron, FDA, Reblozyl, myelodysplastic syndromes
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Sat, 11/9/19 - 12:13 pm
Tags:
Celgene, Acceleron, Reblozyl, anemia, beta thalassemia
Another failed midstage asset for Acceleron, another pipeline test dumped
Fierce Biotech
Tue, 09/17/19 - 10:19 am
Tags:
Acceleron, clinical trials, ACE-083
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Tue, 09/10/19 - 11:06 am
Tags:
Acceleron, orphan drugs, sotatercept, PAH
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Tue, 06/4/19 - 11:02 am
Tags:
Celgene, Bristol-Myers Squibb, Acceleron, luspatercept, MDS, beta thalassemia
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Fri, 04/5/19 - 11:42 am
Tags:
Celgene, Acceleron, luspatercept, myelodysplastic syndrome, beta thalassemia
Fri, 04/5/19 - 10:44 am
Tags:
Celgene, Acceleron, luspatercept
Acceleron, Stemline price upsized follow-ons
BioCentury
Wed, 01/16/19 - 11:57 am
Tags:
Acceleron, Stemline Therapeutics, Celgene, Elzonris tagraxofusp-erzs
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Fri, 01/11/19 - 09:58 am
Tags:
Celgene, M&A, Juno Therapeutics, Kite Therapeutics, Bluebird Bio, Agios Pharmaceuticals, Jounce Therapeutics, BieGene, Acceleron
BMS deal weighs on Celgene partners
BioCentury
Thu, 01/3/19 - 11:45 pm
Tags:
M&A, Celgene, Bristol-Myers Squibb, Acceleron, BeiGene
Top Biotech Stocks to Watch at ASH 2018
Yahoo/Motley Fool
Sun, 12/2/18 - 12:37 pm
Tags:
ASH2018, Celgene, Bluebird Bio, Acceleron

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.